Cogent Biosciences, Inc. (NASDAQ:COGT)
| Market Cap | $4.97B-14.8% |
| Revenue (ttm) | $0 |
| Net Income | -$407.68M-38.5% |
| EPS | -$2.32+6.1% |
| Shares Out | 173.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,150,715 |
| Open | $28.77 |
| Previous Close | $29.14 |
| Day's Range | $28.45 - $29.02 |
| 52-Week Range | $27.73 - $43.73 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | $50.67(+77.42%) |
| Earnings Date | Feb 16, 2027 |
About COGT
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating COGT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 16, 2027Earnings report
$COGT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in COGT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by COGT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
COGT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New COGT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to COGT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in COGT
| VTIVanguard Morningstar Total Stock Market ETF | $166.01M |
| IWMiShares Russell 2000 ETF | $126.94M |
| XBIState Street SPDR S&P Biotech ETF | $120.03M |
| VBVanguard Morningstar Small-Cap ETF | $118.72M |
| VBRVanguard Morningstar Small-Cap Value ETF | $77.32M |
| VXFVanguard Extended Market ETF | $62.74M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from COGT’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 1Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| LFSC | F/M Emerald Life Sciences Innovation ETF | 5.38% |
| HLTH | Tema Healthcare AI ETF | 4.63% |
| CANC | Tema Oncology ETF | 4.37% |
| XBI | State Street SPDR S&P Biotech ETF | 1.15% |
| TDNA | T. Rowe Price Biotech ETF | 0.83% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.66% |
| ACSG | American Century Small Cap Growth Insights ETF | 0.40% |
| BMED | iShares Health Innovation Active ETF | 0.36% |
| ESSC | Eventide Small Cap ETF | 0.35% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.35% |
| FSML | Franklin Small Cap Enhanced ETF | 0.34% |
| HELX | Franklin Genomic Advancements ETF | 0.33% |
Weight is the stock’s share of each fund’s holdings.